<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Betamethasone (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Betamethasone (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Betamethasone (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95150" href="/d/html/95150.html" rel="external">see "Betamethasone (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="95148" href="/d/html/95148.html" rel="external">see "Betamethasone (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F23780847"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Celestone Soluspan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871718"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Celestone Soluspan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F23780851"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Systemic</li></ul></div>
<div class="block doa drugH1Div" id="F23780883"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information</b>
<b>:</b> Dosages expressed as combined amount of betamethasone sodium phosphate and betamethasone acetate; 1 mg is equivalent to betamethasone sodium phosphate 0.5 mg and betamethasone acetate 0.5 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: Usual dosage range:</b>
<b>IM:</b> Initial: 0.25 to 9 mg/day (based on severity of disease and patient response).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab63a99e-e22b-43c4-ad1a-4c2eeb03d756">Antenatal fetal maturation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antenatal fetal maturation (off-label use): IM:</b> 12 mg every 24 hours for a total of 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26695585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26695585'])">Ref</a></span>). A single course of betamethasone is recommended for women between 24 and 34 weeks' gestation, including those with ruptured membranes or multiple gestations, who are at risk of delivering within 7 days. A single course may be appropriate in some women beginning at 23 weeks' gestation or late preterm (between 34 0/7 weeks' and 36 6/7 weeks' gestation). A single repeat course may be considered in some women with pregnancies less than 34 weeks' gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26695585','lexi-content-ref-32080050','lexi-content-ref-28742678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26695585','lexi-content-ref-32080050','lexi-content-ref-28742678'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="377f1977-0678-44e0-b73e-3dd1020ff54a">Bursitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bursitis (other than of foot):</b>
<b>Intra-articular:</b> 3 to 6 mg (0.5 to 1 mL) for one dose; additional injections may be required for acute exacerbations or chronic conditions; generally, injections should be separated by a minimum of 4 to 6 weeks and limited to ≤4 injections per year. If symptoms are not improved after 1 or 2 injections, additional injections are unlikely to provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12152964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12152964'])">Ref</a></span>); following resolution of acute episodes, reduced doses may be warranted for chronic conditions.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a5eab12-f12a-4079-8d9b-3c3b902004ca">Dermatologic conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatologic conditions:</b>
<b>Intradermal:</b> 1.2 mg/cm<sup>2</sup> (0.2 mL/cm<sup>2</sup>) into lesion for one dose (maximum: 6 mg [1 mL] weekly).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1abc690c-2083-49dd-8453-f81cc1a58c15">Foot disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Foot disorders:</b>
<b>Intra-articular:</b> 1.5 mg to 6 mg (0.25 to 1 mL) per dose. Dose is based upon condition; additional injections (when required) should generally be separated by a minimum of 4 to 6 weeks and limited to ≤4 injections per year. If symptoms are not improved after 1 or 2 injections, additional injections are unlikely to provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12152964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12152964'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Bursitis: 1.5 mg to 3 mg (0.25 to 0.5 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Tenosynovitis: 3 mg (0.5 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Acute gouty arthritis: 3 mg to 6 mg (0.5 to 1 mL).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af40f154-7312-412d-a28e-8e77cdc833ae">Multiple sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis: </b>
<b>Note: </b>Treatment guidelines recommend the use of high-dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22156988','lexi-content-ref-25340249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22156988','lexi-content-ref-25340249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 30 mg daily for 1 week, followed by 12 mg every other day for 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7a13952c-2c0f-4843-ad82-f3b30deda07d">Rheumatoid and osteoarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid and osteoarthritis:</b>
<b>Intra-articular:</b> 3 mg to 12 mg (0.5 to 2 mL) for one dose. Dose is based upon the joint size:</p>
<p style="text-indent:-2em;margin-left:4em;">Very large (eg, hip): 6 to 12 mg (1 to 2 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Large (eg, knee, ankle, shoulder): 6 mg (1 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Medium (eg, elbow, wrist): 3 mg to 6 mg (0.5 to 1 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Small (eg, inter- or metacarpophalangeal, sternoclavicular): 1.5 mg to 3 mg (0.25 to 0.5 mL).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26b30cd8-5503-442d-a0be-dd0402ac4a57">Tenosynovitis, peritendinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tenosynovitis (other than of foot), peritendinitis:</b>
<b>Intra-articular:</b> 1.5 to 6 mg (0.25 to 1 mL) depending on joint size for one dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12152964','lexi-content-ref-19725488','lexi-content-ref-28783767','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12152964','lexi-content-ref-19725488','lexi-content-ref-28783767','lexi-content-ref-Manu.1'])">Ref</a></span>); additional injections (when required) should generally be separated by a minimum of 4 to 6 weeks and limited to ≤4 injections per year. If symptoms are not improved after 1 or 2 injections, additional injections are unlikely to provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12152964','lexi-content-ref-28783767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12152964','lexi-content-ref-28783767'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990324"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987666"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F23780884"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use the lowest effective dose.</p></div>
<div class="block dop drugH1Div" id="F23780882"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="95148" href="/d/html/95148.html" rel="external">see "Betamethasone (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosages expressed as combined amount of betamethasone sodium phosphate and betamethasone acetate; 1 mg is equivalent to betamethasone sodium phosphate 0.5 mg and betamethasone acetate 0.5 mg. Dosage should be based on severity of disease and patient response; use lowest effective dose for shortest period of time to avoid HPA axis suppression.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b3396b8-258d-476c-824c-7b20a20a0015">Inflammatory and allergic conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammatory and allergic conditions:</b> Infants, Children, and Adolescents: IM: Initial: 0.02 to 0.3 mg/kg/day (0.6 to 9 mg/m<sup>2</sup>/day) in 3 or 4 divided doses</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="426444d5-e051-4867-aca4-dc9918ba9f0f">Infantile hemangioma, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile hemangioma, severe:</b> Limited data available: Infants and Children: Intralesional: Dosage dependent upon size of lesion: Commonly reported: 6 mg administered as a 6 mg/mL (in combination with triamcinolone injection) divided into multiple injections along the lesion perimeter; reported range: 1.5 to 18 mg/dose; doses usually administered every 8 to 14 weeks; reported range: 6 to 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18054392','lexi-content-ref-7944196','lexi-content-ref-4034770','lexi-content-ref-21042190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18054392','lexi-content-ref-7944196','lexi-content-ref-4034770','lexi-content-ref-21042190'])">Ref</a></span>). Dosing based on small trials and case-series, mostly reported in infants and children ≤4 years of age. The largest experience (n=70, age range: 2 months to 12 years) prospectively used a betamethasone/triamcinolone combination injection (1.5 to 18 mg betamethasone acetate) and showed that 89.23% of lesions with an initial volume &lt;20 cc<sup>3</sup> regressed by more than 50%, but only 22.2% of lesions with an initial volume &gt;20 cc<sup>3</sup> displayed a good or excellent response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7944196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7944196'])">Ref</a></span>). Another trial (n=25, age range: 7 weeks to 2 years) used lower doses of 3 to 12 mg (in combination with triamcinolone); 16 patients experienced a marked response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4034770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4034770'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073521"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073522"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F23780866"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiomegaly, circulatory shock, edema, embolism (fat), hypertension, hypertrophic cardiomyopathy, myocardial rupture (following recent MI), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Abnormal sensory symptoms, arachnoiditis, depression, emotional lability, euphoria, headache, increased intracranial pressure, insomnia, malaise, meningitis, myasthenia, neuritis, neuropathy, paraplegia, paresthesia, personality changes, pseudotumor cerebri, psychic disorder, seizure, spinal cord compression, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, diaphoresis, ecchymoses, erythema, exfoliation of skin, fragile skin, hyperpigmentation, hypertrichosis, hypopigmentation, skin atrophy, skin rash, subcutaneous atrophy, suppression of skin test reaction, thinning hair, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Amenorrhea, calcinosis, cushingoid state, decreased glucose tolerance, decreased serum potassium, fluid retention, glycosuria, growth suppression (pediatric), hirsutism, HPA-axis suppression, hypokalemic alkalosis, impaired glucose tolerance/prediabetes, insulin resistance (increased requirements for insulin or oral hyperglycemic agents), moon face, negative nitrogen balance, protein catabolism, sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal distention, change in bowel habits, hiccups, increased appetite, intestinal perforation, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Bladder dysfunction, spermatozoa disorder (decreased motility and number)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Petechia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Hepatomegaly, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Infection (decreased resistance), sterile abscess</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction (intra-articular use). postinjection flare (intra-articular use)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Amyotrophy, aseptic necrosis of femoral head, aseptic necrosis of humeral head, bone fracture, Charcot arthropathy, lipotrophy, myopathy, osteoporosis, rupture of tendon, steroid myopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blindness, blurred vision, cataract, exophthalmos, glaucoma, increased intraocular pressure, papilledema</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Wound healing impairment</p></div>
<div class="block coi drugH1Div" id="F23780863"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to any component of the formulation; IM administration contraindicated in immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Herpes simplex of the eye; systemic fungal infections; vaccinia; cerebral malaria; use in areas with local infection.</p></div>
<div class="block war drugH1Div" id="F23780864"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. In stressful situations, HPA axis-suppressed patients should receive adequate supplementation with natural glucocorticoids (hydrocortisone or cortisone) rather than betamethasone (due to lack of mineralocorticoid activity).</p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate infections, or limit response to killed or inactivated vaccines. Special pathogens (<i>Amoeba</i>, <i>Candida</i>, <i>Cryptococcus</i>, <i>Mycobacterium</i>, <i>Nocardia</i>, <i>Pneumocystis</i>, <i>Strongyloides</i>, or <i>Toxoplasma</i>) may be activated or an infection exacerbation may occur (may be fatal). Amebiasis or <i>Strongyloides </i>infections should be particularly ruled out. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with tuberculosis (TB) infection (latent TB) and/or TB reactivity; restrict use in TB disease (active TB) (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with electrolyte disturbances, fluid retention, and hypertension. Dietary modifications may be necessary. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, peptic ulcer, ulcerative colitis) due to perforation risk. Avoid ethanol may enhance gastric mucosal irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and renal function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroidism and decreases in hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For intramuscular, intra-articular or intralesional use only, do not administer intravenously or epidurally (see Epidural injection).</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular injection: May produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. Avoid injection into an infected site. Do not inject into unstable joints. Intra-articular injection may result in damage to joint tissues.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878792"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Adrenal suppression with failure to thrive has been reported in infants after receiving intralesional corticosteroid injections for treatment of hemangioma (Goyal, 2004). May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2007). </p></div>
<div class="block foc drugH1Div" id="F23780904"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestone Soluspan: 6 mg/mL consisting of betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/mL consisting of betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F23780850"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F23780906"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Betamethasone Sod Phos &amp; Acet Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 (3-3) mg/mL (per mL): $9.60 - $13.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Celestone Soluspan Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 (3-3) mg/mL (per mL): $9.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871719"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestone Soluspan: 6 mg/mL consisting of betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (1 mL, 5 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p></div>
<div class="block adm drugH1Div" id="F23780889"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Shake well prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: May be administered intramuscularly.</p>
<p style="text-indent:-2em;margin-left:2em;">Intra-articular: Needle size requirements vary based on the size of the joint to be treated (eg, &lt;25 gauge [hip, knee, shoulder], 25 gauge [wrist, ankle, elbow]) and/or method of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27276101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27276101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bursitis: Inject into affected bursa.</p>
<p style="text-indent:-2em;margin-left:4em;">Rheumatoid or osteoarthritis: Inject into synovial cavity.</p>
<p style="text-indent:-2em;margin-left:4em;">Tendinopathy/tenosynovitis: Inject into affected tendon sheaths (not directly into tendons).</p>
<p style="text-indent:-2em;margin-left:2em;">Intradermal: Inject a uniform depot using a 1 mL (eg, tuberculin) syringe with <sup>1</sup>/<sub>2</sub>-inch needle (typically 26 or 27 gauge) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16741399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16741399'])">Ref</a></span>). Do <b>not</b> inject subcutaneously.</p></div>
<div class="block admp drugH1Div" id="F52614556"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> May be coadministered with a local anesthetic.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do <b>not </b>administer IV.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Shake well prior to use; administer deep IM injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Intrabursal: Tendinopathy, tenosynovitis: Inject into affected tendon sheaths (not directly into tendons).</p>
<p style="text-indent:-2em;margin-left:4em;">Intralesional: Using a 25-gauge tuberculin syringe with <sup>1</sup>/<sub>2</sub>-inch needle inject a uniform depot; for infantile hemangioma, 26- and 27-gauge needles have been used for administration. Should be injected directly into the lesion area. Do <b>not</b> inject subcutaneously.</p></div>
<div class="block use drugH1Div" id="F23780855"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">
<b>
<i>Intramuscular:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Allergic states:</b> Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dermatologic diseases:</b> Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endocrine disorders:</b> Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. <b>Note:</b> Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastrointestinal diseases:</b> During acute episodes in regional enteritis and ulcerative colitis</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hematologic disorders:</b> Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neoplastic diseases:</b> Palliative management of leukemias and lymphomas</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nervous system:</b> Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. <b>Note</b>: Treatment guidelines recommend the use of high-dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ophthalmic diseases:</b> Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Renal diseases:</b> To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Respiratory diseases:</b> Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rheumatic disorders:</b> Adjunctive therapy for short-term administration in acute gout flares; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Miscellaneous:</b> Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy</p>
<p style="text-indent:0em;margin-top:2em;">
<b>
<i>Intra-articular or soft tissue administration:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjunctive therapy for short-term administration in acute gout flares, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis</p>
<p style="text-indent:0em;margin-top:2em;">
<b>
<i>Intralesional:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum</p></div>
<div class="block off-label drugH1Div" id="F25475190"><span class="drugH1">Use: Off-Label: Adult</span><p>Accelerate fetal lung maturation</p></div>
<div class="block cyt drugH1Div" id="F23780922"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F23780921"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Betamethasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Betamethasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Betamethasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F23780860"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Betamethasone crosses the placenta (Brownfoot 2013) and is partially metabolized by placental enzymes to an inactive metabolite (Murphy 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids during pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Betamethasone is classified as a fluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids (eg, prednisone) are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Antenatal corticosteroid administration promotes fetal lung maturity and is associated with the reduction of intraventricular hemorrhage, necrotizing enterocolitis, neonatal mortality, and respiratory distress syndrome. A single course of betamethasone is recommended for patients between 24 0/7 and 33 6/7 weeks' gestation who are at risk of delivering within 7 days. This recommendation includes those with ruptured membranes or multiple gestations. A single course of betamethasone may be considered for patients beginning at 23 0/7 weeks' gestation who are at risk of delivering within 7 days, in consultation with the family regarding resuscitation. In addition, a single course of betamethasone may be given to patients between 34 0/7 weeks and 36 6/7 weeks who are at risk of preterm delivery within 7 days and who have not previously received corticosteroids if induction or delivery will proceed ≥24 hours and ≤7 days; delivery should not be delayed for administration of antenatal corticosteroids. Use of concomitant tocolytics is not currently recommended and administration of late preterm corticosteroids has not been evaluated in patients with intrauterine infection, multiple gestations, pregestational diabetes, or patients who delivered previously by cesarean section at term. Multiple repeat courses are not recommended. However, in patients with pregnancies less than 34 weeks' gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior, a single repeat course may be considered; use of a repeat course in patients with preterm prelabor rupture of membranes is controversial (ACOG 171 2016; ACOG 217 2020; ACOG 713 2017).</p></div>
<div class="block brc drugH1Div" id="F23780862"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The onset of milk secretion after birth may be delayed and the volume of milk produced may be decreased by antenatal betamethasone therapy; this affect was seen when delivery occurred 3 to 9 days after the betamethasone dose in patients between 28 and 34 weeks' gestation. Antenatal betamethasone therapy did not affect milk production when birth occurred &lt;3 days or &gt;10 days of treatment (Henderson 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfed infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore, recommends that caution be exercised when administering betamethasone to breastfeeding patients. Corticosteroids are generally considered compatible with breastfeeding when used in usual doses; however, monitoring of the breastfeeding infant for adverse reactions is recommended (WHO 2002). Betamethasone is classified as a fluorinated corticosteroid. When systemic corticosteroids are needed in a lactating patient for rheumatic disorders, low doses of nonfluorinated corticosteroids (eg, prednisone) are preferred (ACR [Sammaritano 2020]).</p></div>
<div class="block mop drugH1Div" id="F23780893"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth in children; injection site reactions, risk of infection</p></div>
<div class="block pha drugH1Div" id="F23780870"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation</p></div>
<div class="block phk drugH1Div" id="F49638561"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 64% (Peterson 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (Peterson 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 6.5 hours (Peterson 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IV: 10 to 36 minutes (Peterson 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;5% as unchanged drug) (Peterson 1983)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24799663"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Celestone chronodose | Diprofos</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Butasona | Celestone</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Celestone chronodose</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Betnesol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diprophos</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beclonato | Beta long | Betameson moduram | Betaprospan | Betaspan | Betatrinta | Betrospam | Biproslan | Celestone | Celestone soluspan | Diprobet | Diprobeta | Diprocort | Diprop betam+fosf.diss.betam | Diprospan | Duoflam | Fosfato Dissodico de Betametasona</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Betametasona | Betametasona fosfato disodico + betametasona dipropionato | Betametasona mk | Betametasona sodio fosfato | Celestone | Diprospan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Celestan depot</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Becloderm Duo | Celestone cronodose | Diprospan | Inflacor | Valerpan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betametasona | Diprospan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Celestan depot</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diprofos | Durafos</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betnesol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Celestone chronodose</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Betamethasone | Bexilus | Solubet | Stemin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bentelan | Betametasone doc | Betametasone EG | Betametasone lfm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Celestone chronodose</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rinderon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Celestan depot</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Betnesol | Celestone | Diprophos</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Betespan | Celestone soluspan | Diprospan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bufencon | Celestone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Celestan depot</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cortixyl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Diprospan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Betnesol | Rekabson</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diprophos</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betamethasone sodium phosphate and betamethasone acetate | Celestone soluspan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Betnasol | Celesdepot</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Betasone (Julphar) | Diprofos</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Betacort | Celestone | Celestone chronodose | Diprofos</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Celestone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Betnesol | Cales | Celestone chronodose | Dipromed</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betamethasone | Betason | Betasone | Bufencon | Diprospan | Vethasone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Celestone cronodose | Cortipyren</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betagen | Betagen solspen | Celestone | Celestone soluspan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Celestone soluspan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28742678">
<a name="28742678"></a>ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 713: Antenatal corticosteroid therapy for fetal maturation. <i>Obstet Gynecol</i>. 2017;130(2):e102-e109. doi:10.1097/AOG.0000000000002237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/28742678/pubmed" id="28742678" target="_blank">28742678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26695585">
<a name="26695585"></a>ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 171: Management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.1097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32080050">
<a name="32080050"></a>ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 217: Prelabor rupture of membranes.<i> Obstet Gynecol</i>. 2020;135(3):e80‐e97. doi:10.1097/AOG.0000000000003700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/32080050/pubmed" id="32080050" target="_blank">32080050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22018758">
<a name="22018758"></a>Bae YS, Van Voorhees AS, Hsu S, et al, "Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation," <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/22018758/pubmed" id="22018758" target="_blank">22018758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Betamethasone sodium phosphate and betamethasone acetate injectable suspension [prescribing information]. Shirley, NY: American Regent, Inc; December 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7618934">
<a name="7618934"></a>Boot AM, Nauta J, Hokken-Koelega AC, et al, “Renal Transplantation and Osteoporosis,” <i>Arch Dis Child</i>, 1995, 72(6):502-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/7618934/pubmed" id="7618934" target="_blank">7618934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1282440">
<a name="1282440"></a>Bowman H and Lennard TW, “Immunosuppressive Drugs,” <i>Br J Hosp Med</i>, 1992, 48(9):570-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/1282440/pubmed" id="1282440" target="_blank">1282440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23990333">
<a name="23990333"></a>Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2013;(8):CD006764. doi:10.1002/14651858.CD006764.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/23990333/pubmed" id="23990333" target="_blank">23990333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18054392">
<a name="18054392"></a>Buckmiller LM, Francis CL, Glade RS. Intralesional steroid injection for proliferative parotid hemangiomas. <i>Int J Pediatr Otorhinolaryngo</i>. 2008,72:81-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/18054392/pubmed" id="18054392" target="_blank">18054392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-10; quiz 427. doi: 10.1016/j.jaad.2013.09.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12152964">
<a name="12152964"></a>Cardone DA, Tallia AF. Joint and soft tissue injection. <i>Am Fam Physician</i>. 2002;66(2):283-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/12152964/pubmed" id="12152964" target="_blank">12152964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celestone.1">
<a name="Celestone.1"></a>Celestone Soluspan (betamethasone) [prescribing information]. Jersey City, NJ: Organnon LLC; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celestone.2">
<a name="Celestone.2"></a>Celestone Soluspan (betamethasone) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7944196">
<a name="7944196"></a>Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. <i>Ann Plast Surg</i>. 1994;33(1):46-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/7944196/pubmed" id="7944196" target="_blank">7944196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19725488">
<a name="19725488"></a>Churgay CA. Diagnosis and treatment of biceps tendinitis and tendinosis. <i>Am Fam Physician</i>. 2009;80(5):470-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/19725488/pubmed" id="19725488" target="_blank">19725488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS and Stewart PM, “Corticosteroid Insufficiency in Acutely Ill Patients,” <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779267">
<a name="11779267"></a>Coursin DB and Wood KE, “Corticosteroid Supplementation for Adrenal Insufficiency,” <i>JAMA</i>, 2002, 287(2):236-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/11779267/pubmed" id="11779267" target="_blank">11779267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2665800">
<a name="2665800"></a>Gamsu HR, Mullinger BM, Donnai P, et al, “Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,” <i>Br J Obstet Gynaecol</i>, 1989, 96(4):401-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/2665800/pubmed" id="2665800" target="_blank">2665800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15019396">
<a name="15019396"></a>Goyal R, Watts P, Lane CM, Beck L, Gregory JW. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. <i>Ophthalmology</i>. 2004;111(2):389-395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/15019396/pubmed" id="15019396" target="_blank">15019396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7709459">
<a name="7709459"></a>Grotz WH, Mundinger FA, Gugel B, et al, “Bone Mineral Density After Kidney Transplantation: A Cross-Sectional Study in 190-Graft Recipients Up to 20 Years After Transplantation,” <i>Transplantation</i>, 1995, 59(7):982-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/7709459/pubmed" id="7709459" target="_blank">7709459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-349394">
<a name="349394"></a>Gutin PH, “Corticosteroid Therapy in Patients With Brain Tumors,” <i>Natl Cancer Inst Monogr</i>, 1977, 46:151-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/349394/pubmed" id="349394" target="_blank">349394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26842679">
<a name="26842679"></a>Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al; NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. <i>N Engl J Med</i>. 2016; 374(14):1311-1320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/26842679/pubmed" id="26842679" target="_blank">26842679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18166549">
<a name="18166549"></a>Henderson JJ, Hartmann PE, Newnham JP, et al, “Effect of Preterm Birth and Antenatal Corticosteroid Treatment on Lactogenesis II in Women,” <i>Pediatrics</i>, 2008, 121(1):e92-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/18166549/pubmed" id="18166549" target="_blank">18166549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8060761">
<a name="8060761"></a>Kimberly RP, “Glucocorticoids,” <i>Curr Opin Rheumatol</i>, 1994, 6(3):273-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/8060761/pubmed" id="8060761" target="_blank">8060761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22112526">
<a name="22112526"></a>Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. <i>Obstet Gynecol Surv</i>. 2011;66(10):654-663.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/22112526/pubmed" id="22112526" target="_blank">22112526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4034770">
<a name="4034770"></a>Kushner BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. <i>Plast Reconstruc Surg</i>. 1985;76(4):517-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/4034770/pubmed" id="4034770" target="_blank">4034770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA and Reed BR, "The Use of Dermatologic Drugs in Pregnancy and Lactation," <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. <i>Pediatrics</i>. 2007;119 (Suppl 2):S166-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4561295">
<a name="4561295"></a>Liggins GC and Howie RN, “A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,” <i>Pediatrics</i>, 1972, 50(4):515-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/4561295/pubmed" id="4561295" target="_blank">4561295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16741399">
<a name="16741399"></a>Love GH. Administering an intradermal injection. <i>Nursing</i>. 2006;36(6):20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/16741399/pubmed" id="16741399" target="_blank">16741399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2417096">
<a name="2417096"></a>Lowenthal RM and Jestrimski KW, “Corticosteroid Drugs: Their Role in Oncological Practice,” <i>Med J Aust</i>, 1986, 144(2):81-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/2417096/pubmed" id="2417096" target="_blank">2417096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al, "Use of Glucocorticoids in Pregnancy,"<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18504331">
<a name="18504331"></a>McGee S and Hirschmann J, “Use of Corticosteroids in Treating Infectious Diseases,” <i>Arch Intern Med</i>, 2008, 168(10):1034-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/18504331/pubmed" id="18504331" target="_blank">18504331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33368142">
<a name="33368142"></a>McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2020;12(12):CD004454. doi:10.1002/14651858.CD004454.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/33368142/pubmed" id="33368142" target="_blank">33368142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32274772">
<a name="32274772"></a>McIntosh JJ. Corticosteroid guidance for pregnancy during COVID-19 pandemic [published online April 9, 2020]. <i>Am J Perinatol</i>. 2020. doi:10.1055/s-0040-1709684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/32274772/pubmed" id="32274772" target="_blank">32274772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1680599">
<a name="1680599"></a>Murphy CM, Coonce SL, and Simon PA, “Treatment of Asthma in Children,” <i>Clin Pharm</i>, 1991, 10(9):685-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/1680599/pubmed" id="1680599" target="_blank">1680599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549198">
<a name="16549198"></a>Murphy VE, Fittock RJ, Zarzycki PK, et al, “Metabolism of Synthetic Steroids by the Human Placenta,” <i>Placenta</i>, 2007, 28(1):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/16549198/pubmed" id="16549198" target="_blank">16549198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25340249">
<a name="25340249"></a>National Institute for Health and Care Excellence (NICE) (UK). Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Multiple sclerosis in adults: management. Clinical guideline 186. https://www.nice.org.uk/guidance/cg186. Published October 8, 2014. Accessed October 21, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/25340249/pubmed" id="25340249" target="_blank">25340249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Bjorkhem I, et al, "Prednisolone Excretion in Human Milk," <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11091360">
<a name="11091360"></a>Park-Wyllie L, Mazzotta P, Pastuszak A, et al, "Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies," <i>Teratology</i>, 2000, 62(6):385-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/11091360/pubmed" id="11091360" target="_blank">11091360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6662164">
<a name="6662164"></a>Petersen MC, Nation RL, McBride WG, Ashley JJ, Moore RG. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. <i>Eur J Clin Pharmacol</i>. 1983;25(5):643-650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/6662164/pubmed" id="6662164" target="_blank">6662164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32248521">
<a name="32248521"></a>Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals [published online April 4, 2020]. <i>Int J Gynaecol Obstet</i>. 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/32248521/pubmed" id="32248521" target="_blank">32248521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745915">
<a name="14745915"></a>Pradat P, Robert-Gnansia E, Di Tanna GL, et al, “First Trimester Exposure to Corticosteroids and Oral Clefts,” <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/14745915/pubmed" id="14745915" target="_blank">14745915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21042190">
<a name="21042190"></a>Prasetyono TO, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review.<i> Ann Plast Surg</i>. 2011;66(1):98-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/21042190/pubmed" id="21042190" target="_blank">21042190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27276101">
<a name="27276101"></a>Rastogi AK, Davis KW, Ross A, Rosas HG. Fundamentals of joint injection. <i>AJR Am J Roentgenol</i>. 2016;207(3):484-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/27276101/pubmed" id="27276101" target="_blank">27276101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129444">
<a name="8129444"></a>Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, “Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,” <i>Arch Dis Child</i>, 1994, 70(2):151-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/8129444/pubmed" id="8129444" target="_blank">8129444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28321847">
<a name="28321847"></a>Roberts D, Brown J, Medley N, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2017;3:CD004454. doi: 10.1002/14651858.CD004454.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/28321847/pubmed" id="28321847" target="_blank">28321847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22156988">
<a name="22156988"></a>Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(24):2128-2134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/22156988/pubmed" id="22156988" target="_blank">22156988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SMFM.1">
<a name="SMFM.1"></a>Society for Maternal Fetal Medicine (SMFM) and the Society for Obstetric Anesthesia and Perinatology (SOAP). Revise Labor and Delivery COVID-19 Considerations (April 14, 2020; updated from an earlier version on March 27, 2020). Available at https://www.smfm.org/covidclinical. Accessed April 17, 2020</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26992737">
<a name="26992737"></a>Society of Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Statement: Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. <i>Am J Obstet Gynecol. </i>2016;215(2):B13-15. doi: 10.1016/j.ajog.2016.03.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/26992737/pubmed" id="26992737" target="_blank">26992737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28783767">
<a name="28783767"></a>Waryasz GR, Borenstein T, Tambone R, Gil JA, DaSilva M. Hand and arm pain: a pictorial guide to injections. <i>J Fam Pract</i>. 2017;66(8):492-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-systemic-drug-information/abstract-text/28783767/pubmed" id="28783767" target="_blank">28783767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li></ol></div><div id="topicVersionRevision">Topic 95043 Version 288.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
